№ files_lp_3_process_7_064974
File format: docx Character count: 76977 File size: 539 KB
Ixazomib in combination with lenalidomide and dexamethasone is proposed for the treatment of patients with relapsed and/or refractory multiple myeloma in Australia under the Section 100 Highly Specialised Drugs Program.
Year: 2016
Region / city: Australia
Topic: Multiple myeloma treatment
Document type: Submission for listing consideration
Organ / institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: Takeda Pharmaceuticals Australia Pty Ltd
Target audience: PBAC, healthcare professionals
Period of validity: Ongoing treatment
Approval date: 15 November 2016
Date of changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCESINGLE TECHNOLOGY APPRAISALAPPEAL HEARINGAdvice on isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID4067]: Decision of the panel.
Year: 2024
Region / city: United Kingdom
Topic: Health technology assessment
Document type: Appeal hearing report
Organization: National Institute for Health and Care Excellence (NICE)
Author: NICE
Target audience: Healthcare professionals, industry representatives, public
Period of validity: Not specified
Approval date: 23 September 2024
Date of changes: Not specified
Decision: Paddy Lee – Australian Harness Racing Rule 190(1) – Dexamethasone Positive in Keayang Xena
Date: 1 March 2024
Region/City: Melton, Australia
Subject: Horse Racing, Doping Violation
Document Type: Legal Decision
Authority/Institution: Harness Racing Victoria, Victorian Racing Tribunal
Author: Mark Howard, Registrar, Victorian Racing Tribunal
Target Audience: Horse Racing Professionals, Legal Experts
Period of Validity: 3 February 2023
Date of Approval: 1 March 2024
Possible Side Effects of Velcade, Revlimid, Dexamethasone (Table Version Date: December 23, 2022)
Year: 2022
Region / City: Not specified
Topic: Health / Medication Side Effects
Document Type: Medical Information
Organ / Institution: Not specified
Author: Not specified
Target Audience: Healthcare professionals, patients
Effective Period: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Context: A medical source providing information on the potential side effects of Velcade, Revlimid, and Dexamethasone, organized by frequency and severity.
DEXAMETHASONE 700 ΜG IMPLANT; OZURDEX®; ALLERGAN AUSTRALIA PTY LIMITED
Year: 2015
Region / City: Australia
Topic: Pharmaceutical submission
Document Type: Submission for Authority Required Listing
Institution: Medical Services Advisory Committee (MSAC)
Author: Allergan Australia Pty Limited
Target Audience: Healthcare professionals, Medical Services Advisory Committee, Pharmaceutical Regulators
Period of Validity: Indefinite
Approval Date: Not specified
Modification Date: Not specified
Treatment: Diabetic Macular Oedema (DME)
Indication: Visual impairment due to centre-involving DME
Restriction: Authority Required (streamlined)
Clinical Criteria: Diabetic Macular Oedema, Reduced Visual Acuity ≤ 6/12 Snellen
Population Criteria: Adults, pseudophakic or cataract surgery scheduled
Price: Special pricing arrangements
Limitations: Discontinuation of treatment if ≥ 15 letter decrease in best corrected visual acuity (BCVA)
Formulation: 700 µg dexamethasone in a solid polymer drug delivery system
Comparator: Ranibizumab, Bevacizumab
Context: Submission for PBS listing of dexamethasone implant for treating diabetic macular oedema in patients with pseudophakic eyes or those scheduled for cataract surgery.
Quality by Design Based Pharmaceutical Development Report of Cost-Effective Dexamethasone Tablets 20 mg for Regulatory Submission
Year: Not specified
Region / Market context: United States, European Union, India
Field: Pharmaceutical development
Document type: Pharmaceutical development report
Drug product: Dexamethasone Tablets 20 mg
Therapeutic area: Oncology and anti-inflammatory therapy
Indication mentioned: Multiple myeloma adjunct therapy
Development approach: Quality by Design (QbD)
Reference product: HEMADY™ (Dexamethasone) Tablets 20 mg
Reference product manufacturer: Dexcel Pharma Technologies Ltd, Israel
Reference product distributor: Acrotech Biopharma Inc, USA
Active pharmaceutical ingredient: Dexamethasone (micronized API)
Key excipients: Lactose Monohydrate, Corn Starch, Povidone, Sodium Starch Glycollate Type A, Magnesium Stearate
Manufacturing process: Direct blending and compression
Critical Material Attribute (CMA): API particle size distribution below 10 microns
Critical Process Parameter (CPP): Blending time (15 minutes pre-lubrication, 5 minutes lubrication)
Critical Quality Attributes (CQA): Blend flow, hardness, dissolution
Stability testing conditions: 40°C ± 2°C / 75% RH ± 5% RH for 6 months
Packaging evaluated: Bottle and blister pack
Regulatory framework referenced: ICH Q8 (R2), ICH stability guidelines
Supporting regulatory sources: US DMF, CEP, USP, BP, Ph.Eur
Related patent referenced: US10,537,585 B2 (21 January 2020)
Primary objective: Development of a cost-effective bioequivalent dexamethasone tablet formulation
Topics: IXAZOMIB lenalidomide dexamethasone